Innate Pharma is issuing new shares at a fixed €1.70 each through Stifel and BTIG. Year-end cash fell to €28.1 million at December 31, 2025, from €66.4 million a year earlier.
Latest Innate Pharma SA news
We have not published a story on Innate Pharma SA yet. When there is news, it will appear here.
Latest balance sheet, Dec 31, 2025 (20-F): cash and equivalents €28.1 million, plus short-term investments of €6.2 million, €34.3 million in all.
Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.
Questions about Innate Pharma SA
What is the ticker symbol of Innate Pharma SA?
Innate Pharma SA trades under the ticker IPH on EURONEXT.
Where is Innate Pharma SA listed?
Innate Pharma SA is listed on EURONEXT. Our directory also records these other listings: DUS:IDD; EUROTLX:4IPH; FWB:IDD; GETTEX:IDD; HAM:IDD; HAN:IDD; LS:A0LCUJ; LSIN:0EVI; LSX:A0LCUJ; MUN:IDD; NASDAQ:IPHA; SWB:IDD; TRADEGATE:IDD; XETR:IDD.
What is the SEC CIK of Innate Pharma SA?
The SEC Central Index Key (CIK) for Innate Pharma SA is 1598599. Its filings are on SEC EDGAR.
How many shares does Innate Pharma SA have outstanding?
93,719,323 shares as of 2025-12-31, per the cover page of its 20-F filed 2026-04-01.
Which country or territory is Innate Pharma SA listed under?
Our directory records Innate Pharma SA under France.
What does Innate Pharma SA do?
Our directory classifies Innate Pharma SA as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
What is the ISIN of Innate Pharma SA?
The ISIN recorded for Innate Pharma SA is FR0010331421.
Does aibio.space cover Innate Pharma SA?
aibio.space lists Innate Pharma SA among 2,820 public biotech companies and publishes its news here as stories appear.
Where is Innate Pharma SA incorporated?
SEC records list its state or country of incorporation as I0.
What is the latest Innate Pharma SA (IPH) stock news?
Our latest story on Innate Pharma SA, dated Aug 19, 2026: "Innate Pharma files subscription agreement for new shares at €1.70 each". Innate Pharma is issuing new shares at a fixed €1.70 each through Stifel and BTIG. Year-end cash fell to €28.1 million at December 31, 2025, from €66.4 million a year earlier. Source.
What is Innate Pharma SA's latest stock offering or financing news?
Our latest financing story, dated Aug 19, 2026: "Innate Pharma files subscription agreement for new shares at €1.70 each". Innate Pharma is issuing new shares at a fixed €1.70 each through Stifel and BTIG. Year-end cash fell to €28.1 million at December 31, 2025, from €66.4 million a year earlier. Source.
Who were the underwriters or placement agents on Innate Pharma SA's offering?
From our story: Stifel Europe Securities SAS and BTIG, LLC are the placement agents under a placement agreement dated the same day as the subscription form. Source.
Is Innate Pharma SA a smaller reporting company?
SEC records list Innate Pharma SA's filer category as: Accelerated filer.
Where is Innate Pharma SA headquartered?
SEC records list its business address as 117 AVENUE DE LUMINY, MARSEILLE, 13009.
When does Innate Pharma SA's fiscal year end?
Innate Pharma SA's fiscal year ends on December 31, per SEC records.
Investor discussion: Innate Pharma SA
Members talk about Innate Pharma SA (IPH). Reader posts, not aibio.space reporting, and not investment advice.
Rules
Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
Say whether you hold the stock. Every post states long, short or no position.
No paid or sponsored posts. Do not post for anyone who pays or rewards you.
No buy or sell calls and no price targets.
No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
No personal details and no spam. No links at all for your first 7 days as a member.
Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.
Capital-markets timeline
Financings, listing notices, splits, legal actions and other investor events at Innate Pharma SA, newest first. Each line links the filing it comes from.
Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open EURONEXT:IPH on TradingView.
SEC filings and registration
SEC name
Innate Pharma SA
CIK
1598599
Industry (SIC)
Biological Products, (No Diagnostic Substances) (2836)
US tickers
IPHA (Nasdaq), IPHYF (OTC)
State or country of incorporation
I0
Fiscal year ends
December 31
Filer category
Accelerated filer
Business address
117 AVENUE DE LUMINY, MARSEILLE, 13009
Phone
33430303030
Shares outstanding
93,719,323 as of 2025-12-31 (20-F filed 2026-04-01)
Former names
Innate Pharma, SA
Recent filings (8-K and 6-K are the company's own announcements)
Source: SEC EDGAR, retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.
Listing details
Innate Pharma SA is a public biotech or pharmaceutical company listed on EURONEXT under the ticker IPH, recorded under France. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.
Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.
Published and maintained by aibio.space. Not investment advice. How we work.
Who manages this pageThis page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio